Targeting Tau in Alzheimer's Disease With Voyager Therapeutics' Al Sandrock, M.D., Ph.D.
About this episode
Al Sandrock discusses the significance of tau in Alzheimer's treatment and the potential of gene therapy.
We love to hear from our listeners. Send us a message. On this week's episode of the Business of Biotech, Al Sandrock, M.D., Ph.D., President and CEO at Voyager Therapeutics, talks about why tau is becoming a central target in Alzheimer’s drug development and how gene therapy delivery across the blood-brain barrier could change what treatment looks like at scale. Sandrock shares his current thinking on the amyloid vs. beta debate (it's likely both) in Alzheimer's disease treatment, the role ...
More episodes of Business Of Biotech
- Late-Stage Development And Commercial Planning With CervoMed's Matt Winton, Ph.D.
- BoB@BIO: Biotech In The Balance With Ovid Therapeutics' Dr. Jeremy Levin
- BoB@BIO: Biotech Investing And Deals With Sofinnova's Maha Radhakrishnan, M.D.
- Keeping An Early-Stage Cell Therapy Biotech In The Black With IN8bio's William Ho
- Drug Launch Success In A Changing Commercial Landscape With ACMA's William Soliman, Ph.D.
Explore listener stats, chart rankings, contacts and more on the Business Of Biotech podcast page.